Ardos creates software solutions within radiation therapy to help battle cancer. We are an academic spin-out from Aarhus University Hospital and the founders have worked clinically and academically in the field for more than a decade. Our first product, DoseTracker, transforms radiation therapy to change the best guess of the dose received by each patient to an exact knowledge of the real dose delivered. DoseTracker provides the treatment team with real-time knowledge-based decision support and the confidence to make informed treatment decisions about when and how to intervene. This offers higher cure rates and fewer adverse effects for patients and allows a reduction in healthcare expenditure and an improved workflow in the radiation therapy departments.
Metastasis, caused by circulating tumor cells (CTC), is a major cause of death in cancer patients. If the circulating cells can be captured and explored, it could potentially help cancer research, drug screening and cancer treatment. The pre-spin out 4C technology has developed a filter using the unique technique of melt electrowriting. The filter has shown to capture CTCs from blood samples followed by direct culturing of the captured cells. The 4C filter brings us one step closer to personalized medicine management for cancer patients.
Cenexum is a startup bio-electronic medicines company focused on bringing quality of life back to patients suffering from chronic disorders associated with the central or peripheral nervous system.
Diagnostic surveillance is key for every disease course. For patients with Cystic Fibrosis (CF) and Chronic Kidney Disease (CKD) we have developed new IP-protected diagnostic concepts that use the patient's urine. These test results inform the caretakers on the critical information if novel CF modulator drugs work in each given CF patient and for the CKD patient group can identify those patients that progress dreadfully fast into final loss of kidney function. This information is decisive to “titrate” therapeutic and lifestyle interventions for improved patient care and guidance. Both concepts have been validated by voice of customer investigations from key opinion leaders in the CF and CKD field that underscore their strong potential.
FusionTherapeutics is a life science spinout developing gene therapy for rare malignant diseases driven by fusion oncogenes utilizing a CRISPR-based platform technology.
The industrial production of Strontium ferrites (magnet type) consists of many complex steps involved in it. Energy consuming processes like ball milling, drying and moulding have to be performed twice or thrice to produce these ferrite based permanent magnets. Our innovation deals with reducing the number of steps involved in the production of these ferrite magnets without compromising on the quality of the magnets. We have filed a European patent (20201547.5-1212) which supports our findings with experimental evidences.
KetLace Biosciences is a spin-out from Aarhus University and Aarhus University Hospital formed by three professors within human metabolism (clinical studies), bioanalytics and chemistry in collaboration with experts within human nutrition and spin-outs.
The company has proprietary rights to combined lactate ketone body esters for treating aging-related diseases.
The esters recapitulate major parts of the human response to exercise by increasing lactate and ketone bodies simultaneously, potentially inducing a number of the beneficial effects of exercise.
The compounds have been tested in mice and humans and the first clinical study within obesity has been preliminary approved by the ethics committee and will be conducted this year.
The target of the company is to get EFSA approval and launch the new compounds as medical supplements to the aging population.
Kripthonite Therapeutics develops a therapy that eliminates oxygen-depleted cancer cells in patients with solid tumors. Oxygen-depletion heightens the most aggressive features of cancers and results in resistance towards radio- and chemotherapy. Our therapy derails energy metabolism in oxygen-depleted cancer cells, which leads to rapid and selective cancer cell killing in vitro and in vivo.
Kvantify helps businesses harness the full potential of quantum and high-performance computers, which is a technology that will revolutionise many aspects of computing, and complement High Performance Computing, in tackling the most valuable business problems in the world. Kvantify works closely with leading companies to develop solutions that address the most difficult computational challenges while focusing on areas where they first expect Quantum Computing to be valuable. This includes life sciences, financial services, and logistics.
Learn more about Kvantify here
Rhinomate is an aiming mechanism that ensures optimal delivery of medicine when using a nasal spray. Research has shown that up to 90% of patients fail to administer nasal spray correctly. This leads to more adverse effects and less efficacy of the applied medicine. Rhinomate is easy to use, cheap to manufacture and has the potential to increase quality of life for millions of people globally.
The inventors Jesper Bille and Milos Fuglsang are both experienced rhinologists at Aarhus University Hospital.
Chronic kidney disease is a global health problem with a prevalence of more than 10% of the global population, and currently there are no effective treatments to tackle this health challenge. Seidun Therapeutics is a strong team of researchers and medicinal chemists with experience in company formation and from the industry. During our research at Aarhus University, we have generated strong proof of concept data showing that a novel family of drugs has a dual positive effect in the kidneys and cardiovascular system, making them ideal candidates to combat the disease. We are looking for funding to continue with our pre-clinical work and from there into clinical trials.
At SymbioMatch, we're revolutionising the agricultural sector by developing customised and effective biofertilisers. Our products are specifically tailored to match unique soil types and high-protein crops. Through extensive soil analysis, plant experiments, and advanced data analysis, we identify the optimal plant-soil-bacteria match, resulting in improved crop yields and more sustainable farming practices.
SAAD Tx wishes to develop personalized medicine to treat Alzheimers disease providing a disease modifying therapy. Targeting the gene in the complete Human genone most often mutated in AD.
UniPotent Therapeutics is a pre-spinout biotech that has made significant advancements in developing a stem cell therapy for Parkinson's disease. The company's groundbreaking approach involves engineering lineage-restricted stem cells that have been shown to efficiently generate the cells affected by Parkinson's disease and demonstrate exciting results in animal models. This innovative method offers a new and potentially transformative treatment option for patients suffering from this debilitating condition. UniPotent Therapeutics has secured substantial innovation funding to support the development of their therapy and is actively conducting pre-clinical studies. Their team of experts in stem cell biology and neurodegenerative diseases is committed to advancing the field of regenerative medicine, and the company is dedicated to bringing this revolutionary therapy to the market. With a focus on improving the lives of Parkinson's patients, UniPotent Therapeutics is well-positioned to make a significant impact in the field of stem cell therapy.
Improving cancer treatment through neurological screenings: A paradigm shift in handling side effects caused by chemotherapy which affects quality of life for more than half of all breast cancer patients.
With Wenemea solution chemotherapy induced peripheral neuropathy (CIPN) can be monitoed easier, leading to earlier action, including improved medication and improved quality of life for breast cancer patients.
A series of community building investor events in Aarhus, Denmark